{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:26:07Z","timestamp":1764433567934},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.farma.2024.02.016","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T11:46:10Z","timestamp":1716810370000},"page":"T171-T175","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] Real-world persistence with dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir-alafenamide among persons with HIV"],"prefix":"10.1016","volume":"48","author":[{"given":"Lorena","family":"Mart\u00edn-Zaragoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"S\u00e1nchez-Rubio-Ferr\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Onteniente-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"G\u00f3mez-Bermejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio Julio","family":"Rodr\u00edguez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Monereo-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Molina-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2024.02.016_bb0005","author":"Panel de expertos de GeSIDA y Plan Nacional sobre el Sida"},{"issue":"4 Suppl 3","key":"10.1016\/j.farma.2024.02.016_bb0010","doi-asserted-by":"crossref","first-page":"19537","DOI":"10.7448\/IAS.17.4.19537","article-title":"Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment","volume":"17","author":"Sweet","year":"2014","journal-title":"J Int AIDS Soc."},{"key":"10.1016\/j.farma.2024.02.016_bb0015","doi-asserted-by":"crossref","DOI":"10.2147\/PPA.S207908","article-title":"Treatment adherence and persistence among HIV-1 patients newly starting treatment","author":"Hines","year":"2019","journal-title":"Patient Prefer Adherence."},{"issue":"1","key":"10.1016\/j.farma.2024.02.016_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res Ther."},{"key":"10.1016\/j.farma.2024.02.016_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2017.01.012","article-title":"Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: a multicentre retrospective cohort study","author":"Lewis","year":"2017","journal-title":"J Infect."},{"issue":"1","key":"10.1016\/j.farma.2024.02.016_bb0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: Terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Heal."},{"issue":"1","key":"10.1016\/j.farma.2024.02.016_bb0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12981-020-00328-6","article-title":"HIV-TR Study Group. Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011\u20132017","volume":"18","author":"Korten","year":"2021","journal-title":"AIDS Res Ther"},{"issue":"11","key":"10.1016\/j.farma.2024.02.016_bb0040","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jiac.2022.07.005","article-title":"Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan","volume":"28","author":"Wang","year":"2022","journal-title":"J Infect Chemother."},{"issue":"6","key":"10.1016\/j.farma.2024.02.016_bb0045","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jac\/dkad102","article-title":"Cohort of the Spanish HIV\/AIDS Research Network (CoRIS). Effectiveness and tolerability of dolutegravir\/lamivudine for the treatment of HIV-1 infection in clinical practice","volume":"78","author":"Su\u00e1rez-Garc\u00eda","year":"2023","journal-title":"J Antimicrob Chemother."},{"issue":"7","key":"10.1016\/j.farma.2024.02.016_bb0050","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV."},{"key":"10.1016\/j.farma.2024.02.016_bb0055","article-title":"Belgian Research on AIDS and HIV Consortium (BREACH). Efficacy, durability, and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium","author":"Nasreddine","year":"2023","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.farma.2024.02.016_bb0060","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/QAD.0000000000001708","article-title":"Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure","volume":"32","author":"Eaton","year":"2018","journal-title":"AIDS"},{"issue":"42","key":"10.1016\/j.farma.2024.02.016_bb0065","doi-asserted-by":"crossref","first-page":"e1677","DOI":"10.1097\/MD.0000000000001677","article-title":"meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens","volume":"94","author":"Clay","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.farma.2024.02.016_bb0070","first-page":"163","article-title":"M\u00e9todos para medir la adherencia terap\u00e9utica","volume":"59","author":"Pag\u00e8s-Puigdemont","year":"2018","journal-title":"Ars Pharm [Internet]"},{"issue":"4","key":"10.1016\/j.farma.2024.02.016_bb0075","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother."}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:15:31Z","timestamp":1722039331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1130634324000606"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.02.016","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Real-world persistence with dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir-alafenamide among persons with HIV","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}